1. Home
  2. |Insights
  3. |Product Safety – Managing the Risks

Product Safety – Managing the Risks

Webinar | 11.25.21, 6:00 AM CST - 8:00 AM CST

For any company marketing a product, managing the risks associated with defective or non-compliant products is a key part of the process, both prior to and during commercialization. In particular, you will first need to determine which regulatory framework applies by mapping out the context in which the product is to be made available. Then, once the product has been placed on the market, you will need to know how to handle the various issues that could arise in relation to safety or regulatory non-compliance. 

During this webinar, we will give you a brief overview of the EU safety regulatory framework for consumer and non-consumer (non-food) products and take a look at recent initiatives, including proposed legislation intended to replace the General Product Safety Directive, and the new authorized representative requirement. We will consider the workings of REACH, the Biocidal Product Regulation (which has become all the more relevant since the COVID-19 pandemic), and the specific regulation of medical devices. 

In addition, we will take a practical look at how you can limit your liability under Belgian law should your product be defective and cause damage. In particular, we will consider product liability, and contractual and hidden defects liability. We will also discuss notifications and recalls. 

Contact: Danica Schiefer DSchiefer@crowell.com

For more information, please visit these areas: Mass Tort, Product, and Consumer Litigation, Product Compliance, Risk Management and Advertising — Brussels Practice, Brussels Practice

Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...